皮膚科臨床アセット　19　水疱性皮膚疾患

出版社： 中山書店
著者：
発行日： 2014-03-20
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784521733562
シリーズ： 皮膚科臨床アセット
電子書籍版： 2014-03-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

16,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

商品紹介

難病として認定されている水疱性類天疱瘡や表皮水疱症などの水疱性疾患は，近年飛躍的に原因が解明されてきた．診断法も保険収載され，より確実に診断が可能となった．治療についても、大量γグロブリン静注療法が保険収載され，今後は抗体医薬なども期待される．医学の進歩に伴い，診断・治療が大きく変化してきた水疱性皮膚疾患について，豊富な写真とともに詳細に解説した一冊．

目次

  • 皮膚科臨床アセット　19　水疱性皮膚疾患

    ―目次―

    I. 自己免疫性水疱症
    　天疱瘡と類縁疾患
    　　１．天疱瘡の定義，疫学，診断基準 （ガイドラインの概要）
    　　２．天疱瘡の病態生理 （デスモグレイン代償説を含む）
    　　３．天疱瘡の血清学的診断法と有用な使い方
    　　４．天疱瘡の臨床，病理所見
    　　　　（尋常性天疱瘡，落葉状天疱瘡，腫瘍随伴性天疱瘡）
    　　５．天疱瘡の亜型
    　　　　（増殖性，紅斑性，疱疹状，薬剤誘発性，IgA）
    　　６．天疱瘡における粘膜疹
    　　７．天疱瘡の治療と予後
    　最新研究からのインサイト
    　　８．デスモゾームによる細胞間接着機構
    　　９．天疱瘡におけるモノクローナル抗体とエピトープ解析
    　　10．天疱瘡モデルマウスから広がる自己免疫病態の理解
    　　11．天疱瘡における棘融解形成機序
    　　12．天疱瘡に対する抗CD20抗体療法の現状
    　類天疱瘡と類縁疾患
    　　13．水疱性類天疱瘡の定義，疫学，診断基準
    　　14．水疱性類天疱瘡の病態生理 （標的抗原の性状を含む）
    　　15　水疱性類天疱瘡および類縁疾患の血清学的診断法
    　　16．水疱性類天疱瘡の臨床，病理，免疫学的所見
    　　17．粘膜類天疱瘡の臨床，病理，免疫学的所見
    　　18．後天性表皮水疱症の臨床，病理，免疫学的所見
    　　19．水疱性類天疱瘡，粘膜類天疱瘡の治療と予後
    　最新研究からのインサイト
    　　20．ヘミデスモゾームによる細胞-基質間接着機構
    　　21．類天疱瘡モデルマウスと病態解析
    　その他の自己免疫水疱性疾患
    　　22．線状IgA皮膚症の診断と治療
    　　23．Duhring疱疹状皮膚炎の診断と治療
    　　24．動物の自己免疫性水疱症

    II. 先天性水疱症
    　　25．遺伝性水疱性疾患の分類と病態
    　　26．単純型表皮水疱症の病因，診断，治療
    　　27．接合部型表皮水疱症の病因，診断，治療
    　　28．栄養障害型表皮水疱症の病因，診断，治療
    　　29．skin fragility症候群の病因，診断，治療
    　　30．Kindler症候群の病因，診断，治療
    　　31．Hailey-Hailey病の病因，診断，治療
    　　32．Darier病の病因，診断，治療
    　　33．表皮水疱症に対する培養表皮細胞療法
    　最新研究からのインサイト
    　　34．表皮水疱症に対する再生医療の現状と未来

    III. その他の水疱性皮膚疾患
    　　35．薬剤性水疱症 （Stevens-Johnson症候群，
    　　　　　中毒性表皮壊死症） の病因，診断，治療
    　　36．ブドウ球菌性熱傷様皮膚症候群（SSSS）と
    　　　　　水疱性膿痂疹の病因，診断，治療
    　　37．ポルフィリン症の病因，診断，治療
    　　38．ウイルスによる水疱性疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 自己免疫性水疱症

P.2 掲載の参考文献
1) Amagai M, Klaus-Kovtum V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemmphigus vulgaris, a disease of cell adhesion. Cell 1991 ; 67 : 869-77.
 
2) Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008 ; 58 : 1043-6.
PubMed
3) 天谷雅行, 谷川瑛子, 清水智子, ほか. 天疱瘡診療ガイドライン. 日皮会誌 2010 ; 120 : 1443-60.
 
4) Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999 ; 40 : 167-70.
PubMed
5) Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorebent assay (ELISA) using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999 ; 140 : 351-7.
PubMed
6) Imamura S. A form for the diagnosis of pemphigus. In : Annual Report of the Intractable Skin Disease Study Group (in Japanese). Ministry of Welfare and Health of Japan ; 1991. p12.
 
7) 天谷雅行. PDAI (Pemphigus Disease Area Index)と新しい天疱瘡評価法の検討 : 稀少難治性皮膚疾患に関する調査研究. 平成20年度総括・分担研究報告書. 2009. pp23-7.
 
P.7 掲載の参考文献
1) Dusek RL, Godsel LM, Green KJ. Discriminating roles of desmosomal cadherins : beyond desmosomal adhesion. J Dermatol Sci 2007 ; 45 : 7-21.
PubMed
2) Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006 ; 355 : 1800-10.
PubMed
3) Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999 ; 103 : 461-8.
PubMed
4) Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 1999 ; 20 : 92-102.
PubMed
5) Rock B, Labib RS, Diaz LA. Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest 1990 ; 85 : 296-9.
PubMed
6) Tsunoda K, Ota T, Aoki M, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003 ; 170 : 2170-8.
PubMed
7) Payne AS, Ishii K, Kacir S, et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005 ; 115 : 888-99.
PubMed
8) Ishii K, Lin C, Siegel DL, et al. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 2008 ; 128 : 939-48.
PubMed
9) Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol 1999 ; 29 : 2233-40.
PubMed
10) Sharma P, Mao X, Payne AS. Beyond steric hindrance : the role of adhesion signaling pathways in the pathogenesis of pemphigus. J Dermatol Sci 2007 ; 48 : 1-14.
PubMed
P.11 掲載の参考文献
1) 天谷雅行, 谷川瑛子, 清水智子, ほか. 天疱瘡診療ガイドライン. 日皮会誌 2010 ; 120 : 1443-60.
 
2) Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997 ; 159 : 2010-7.
PubMed
3) Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay (ELISA) using recombinant desmoglein 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999 ; 140 : 351-7.
PubMed
4) Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006 ; 355 : 1800-10.
PubMed
5) 吉田かおり, 瀬戸早苗, 堀部卓郎, ほか. CLEIA法によるデスモグレインおよびBP180自己抗体測定試薬「ステイシアMEBLuxテストDsg1」「ステイシアMEBLuxテストDsg3」「ステイシアMEBLuxテストBP180」の基礎的検討. 医学と薬学 2013 ; 70 : 989-1000.
 
6) 天谷雅行. 自己免疫性水疱症 (天疱瘡・類天疱瘡). SRL宝函 2013 ; 34 : 12-9.
 
7) Hashimoto T, Ogawa MM, Konohana A, et al. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol 1990 ; 94 : 327-31.
PubMed
8) Hashimoto T, Amagai M, Watanabe K, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995 ; 104 : 829-34.
PubMed
9) Nagata Y, Karashima T, Watt FM, et al. Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol 2001 ; 116 : 556-63.
 
P.17 掲載の参考文献
1) Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006 ; 355 : 1800-10.
PubMed
2) Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009 ; 129 : 2404-10.
PubMed
3) Hata T, Nishimoto S, Nagao K, et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. 2013 ; 191 : 83-90.
 
4) Poot AM, Diericks GFH, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013 ; 169 : 1016-24.
 
P.24 掲載の参考文献
1) Ahmed AR, Blose DA. Pemphigus vegetans. Neumann type and Hallopeau type. Int J Dermatol 1984 ; 23 : 135-41.
PubMed
2) Morizane S, Yamamoto T, Hisamatsu Y, et al. Pemphigus vegetans with IgG and IgA antidesmoglein 3 antibodies. Br J Dermatol 2005 ; 153 : 1236-7.
PubMed
3) Cozzani E, Christana K, Mastrogeacomo A, et al. Pemphigus vegetans Neumann type with anti-desmoglein and anti-periplakin autoantibodies. Eur J Dermatol 2007 ; 17 : 530-3.
PubMed
4) Malik M, Ahmed AR. Concurrence of systemic lupus erythematosus and pemphigus : coincidence or correlation? Dermatology 2007 ; 214 : 231-9.
PubMed
5) Oktarina DAM, Poot AM, Kramer D, et al. The IgG "Lupus-Band" deposition pattern of pemphigus erythematosus : association with the desmoglein 1 ectodomain as revealed by 3 cases. Arch Dermatol 2012 ; 148 : 1173-8.
PubMed
6) Ishi K, Amagai M, Komai A, et al. Desmoglein 1 and desmoglein 3 are the target autoantigens in herpetiform pemphigus. Arch Dermatol 1999 ; 135 : 943-7.
 
7) 藤本亘. 薬剤誘発性天疱瘡. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2002. pp60-5.
 
8) Nagao K, Tanikawa A, Yamamoto N, et al. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamin in drug-induced pemphigus foliaceus. Clin Exp Dermatol 2005 ; 30 : 43-5.
 
9) 西川武二. 表皮細胞間IgA皮膚症. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2002. pp69-71.
 
10) Hashimoto T. Immunopathology of IgA pemphigus. Clin Dermatol 2001 ; 19 : 683-9.
 
11) Hisamatsu Y, Amagai M, Garrod DR, et al. The detection of IgG and IgA autoantibodies to desmocollins 1-3 by enzyme-linked immunosorbent assays using baculovirus-expressed proteins, in atypical pemphigus but not in typical pemphigus. Br J Dermatol 2004 ; 151 : 73-83.
 
12) Kopp T, Sitaru C, Pieczkowski F, et al. IgA pemphigus-occurrence of antidesmocollin 1 and anti-desmoglein 1 antibody reactivity in an individual patient. J Dtsch Dermatol Ges 2006 ; 4 : 1045-50.
 
P.30 掲載の参考文献
1) Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999 ; 103 : 461-8.
PubMed
2) Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999 ; 40 : 167-70.
PubMed
3) 岡博史, 村田隆幸, 斉藤昌孝, ほか. 食道病変を伴った尋常性天疱瘡. 臨皮 1999 ; 53 : 9-14.
 
4) 橋本隆. 腫瘍随伴性天疱瘡. 皮膚病診療 2009 ; 31 : 786-94.
 
5) 橋本隆. 腫瘍随伴性天疱瘡 (Paraneoplastic pemphigus : PNP). 日皮会誌 2001 ; 111 : 1195-203.
 
6) Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus : a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004 ; 40 : 553-62.
PubMed
7) Kimyai-Asadi A, Jih MH. Paraneoplastic pemphigus. Int J Dermatol 2001 ; 40 : 367-72.
PubMed
8) Endo H, Rees TD, Matsue M, et al. Early detection and successful management of oral pemphigus vulgaris : a case report. J Periodontol 2005 ; 76 : 154-60.
PubMed
P.39 掲載の参考文献
1) Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2013 ; 27 : 1285-92.
PubMed
1) 天谷雅行, 谷川瑛子, 清水智子, ほか. 天疱瘡診療ガイドライン. 日皮会誌 2010 ; 120 : 1443-60.
 
2) Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988 ; 124 : 1659-63.
PubMed
2) Rahbar Z, Daneshpazhooh M, Mirshams-Shahshahani M, et al. Pemphigus Disease Activity Measurements : Pemphigus Disease Area Index, Autoimmune Bullous Skin Disorder Intensity Score, and Pemphigus Vulgaris Activity Score. JAMA Dermatol 2014 ; Jan 15. doi : 10.1001/jamadermatol.2013.8175. [Epub ahead of print]
 
3) Amagai M, Ikeda S, Shimizu H, et al. Pemphigus Study Group. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009 ; 60 : 595-603.
 
4) Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996 ; 132 : 1435-9.
PubMed
5) Mignogna MD, Lo Muzio L, Ruoppo E, et al. High-dose intravenous' pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus : a pilot study. J Oral Pathol Med 2002 ; 31 : 339-44.
PubMed
6) Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007 ; 357 : 545-52.
PubMed
7) Mentink LF, Mackenzie MW, Toth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris : PEMPULS trial. Arch Dermatol 2006 ; 142 : 570-6.
PubMed
8) Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008 ; 58 : 1043-6.
PubMed
P.47 掲載の参考文献
1) Kowalczyk AP, Green KJ. Structure, function, and regulation of desmosomes. Prog Mol Biol Transl Sci 2013 ; 116 : 95-118.
PubMed
2) Delva E, Tucker DK, Kowalczyk AP. The desmosome. Cold Spring Harb Perspect Biol 2009 ; 1 : a002543.
PubMed
3) Thomason HA, Scothern A, McHarg S, et al. Desmosomes : adhesive strength and signaling in health and disease. Biochem J 2010 ; 429 : 419-33.
PubMed
4) Saito M, Tucker DK, Kholhorst D, et al. Classical and desmosomal cadherins at a glance. J Cell Sci 2012 ; 125 : 2547-52.
 
5) Owen GR, Stokes DL. Exploring the nature of desmosomal cadherin associations in 3D. Dermatol Res Pract 2010 ; 2010 : 930401.
PubMed
6) Koch PJ, Walsh MJ, Schmelz M, et al. Identification of desmoglein, a constitutive desmosomal glycoprotein, as a member of the cadherin family of cell adhesion molecules. Eur J Cell Biol 1990 ; 53 : 1-12.
PubMed
7) Peifer M, McCrea PD, Green KJ, et al. The vertebrate adhesive junction proteins beta-catenin and plakoglobin and the Drosophila segment polarity gene armadillo form a multigene family with similar properties. J Cell Biol 1992 ; 118 : 681-91.
 
8) Carnahan RH, Rokas A, Gaucher EA, et al. The molecular evolution of the p120-catenin subfamily and its functional associations. PLoS One 2010 ; 5 : e15747.
PubMed
9) Kowalczyk AP, Hatzfeld M, Bornslaeger EA, et al. The head domain of plakophilin-1 binds to desmoplakin and enhances its recruitment to desmosomes. Implications for cutaneous disease. J Biol Chem 1999 ; 274 : 18145-8.
 
10) Sonnenberg A, Liem RK. Plakins in development and disease. Exp Cell Res 2007 ; 313 : 2189-203.
PubMed
11) Jonca N, Leclere EA, Caubet C, et al. Corneodesmosomes and corneodesmosin : from the stratum corneum cohesion to the pathophysiology of genodermatoses. Eur J Dermatol 2011 ; 21 : 35-42.
 
12) 山本明美, 井川哲子, 岸部麻里. コルネオデスモソームが異常になる疾患-Netherton症候群と炎症型peeling skin症候群. 臨皮 2012 ; 66 : 59-62.
 
13) Hobbs RP, Amargo EV, Somasundaram A, et al. The calcium ATPase SERCA2 regulates desmoplakin dymamics and intercellular adhesive strength through modulation of PKCα signaling. FASEB J 2011 ; 25 : 990-1001.
 
14) Pasdar M, Krzeminski KA, Nelson WJ. Regulation of desmosome assembly in MDCK epithelial cells : coordination of membrane core and cytoplasmic plaque domain assembly at the plasma membrane. J Cell Biol 1991 ; 113 : 645-55.
PubMed
15) Godsel LM, Dubash AD, Bass-Zubek AE, et al. Plakophilin 2 couples actomysin remodeling to desmosomal plaque assembly via RhoA. Mol Biol Cell 2010 ; 21 : 2844-59.
 
16) Sekiguchi M, Futei Y, Fujii Y, et al. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 2001 ; 167 : 5439-48.
 
17) Tsunoda K, Ota T, Aoki M, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the aminoterminal adhesive interface of desmoglein 3. J Immunol 2003 ; 170 : 2170-8.
PubMed
18) Berkowitz P, Hu P, Liu Z, et al. Desmosome signaling. Inhibition of p38 MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J Biol Chem 2005 ; 280 : 23778-84.
PubMed
19) Delva E, Jennings JM, Calkins CC, et al. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism. J Biol Chem 2008 ; 283 : 18303-13.
PubMed
20) Saito M, Stahley SN, Caughman CY, et al. Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. PLoS One 2012 ; 7 : e50696.
PubMed
P.53 掲載の参考文献
1) Payne AS, Ishii K, Kacir S, et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005 ; 115 : 888-99.
PubMed
2) Ishii K, Lin C, Siegel DL, et al. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 2008 ; 128 : 939-48.
PubMed
3) Yamagami J, Payne AS, Kacir S, et al. Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. J Clin Invest 2010 ; 120 : 4111-7.
PubMed
4) Tsunoda K, Ota T, Aoki M, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003 ; 170 : 2170-8.
PubMed
5) Di Zenzo G, Di Lullo G, Corti D, et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J Clin Invest 2012 ; 122 : 3781-90.
PubMed
P.59 掲載の参考文献
1) Amagai M, Tsunoda K, Suzuki H, et al. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000 ; 5 : 625-31.
PubMed
1) Yokoyama T, Amagai M. Immune dysregulation of pemphigus in humans and mice. J Dermatol 2010 ; 37 : 205-13.
PubMed
2) 高橋勇人, 天谷雅行. 天疱瘡と表皮特異的T細胞による皮膚炎. 最新医学 2013 ; 68 (6月増刊) : 217-27.
 
3) Tsunoda K, Ota T, Aoki M, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003 ; 4 : 2170-8.
PubMed
4) Boggon TJ, Murray J, Chappuis-Flament S, et al. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 2002 ; 5571 : 1308-13.
PubMed
5) Kawasaki H, Tsunoda K, Hata T, et al. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J Invest Dermatol 2006 ; 12 : 2621-30.
PubMed
6) Tsunoda K, Ota T, Suzuki H, et al. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol 2002 ; 3 : 627-33.
 
7) Takahashi H, Amagai M, Nishikawa T, et al. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J Immunol 2008 ; 2 : 1526-35.
PubMed
8) Takahashi H, Kouno M, Nagao K, et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest 2011 ; 121 : 3677-88.
PubMed
P.65 掲載の参考文献
1) Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991 ; 67 : 869-77.
PubMed
2) Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992 ; 90 : 919-26.
PubMed
3) Civatte A. Diagnostic histopathologique de la dermatite polymorephe douloureuse ou malaidie de Duhring-Brocq. Ann Dermat Et syph 1943 ; 3 : 1.
 
4) Jennings JM, Tucker DK, Kottke MD, et al. Desmosome disassembly in response to pemphigus vulgaris IgG occurs in distinct phases and can be reversed by expression of exogenous Dsg3. J Invest Dermatol 2011 ; 131 : 706-18.
PubMed
5) Yamamoto Y, Aoyama Y, Shu E, et al. Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity. J Biol Chem 2007 ; 282 : 17866-76.
PubMed
6) Delva E, Jennings JM, Calkins CC, et al. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism. J Biol Chem 2008 ; 283 : 18303-13.
PubMed
7) Aoyama Y, Nagai M, Kitajima Y. Binding of pemphigus vulgaris IgG to antigens in desmosome core domains excludes immune complexes rather than directly splitting desmosomes. Br J Dermatol 2010 ; 162 : 1049-55.
PubMed
8) Oktarina DA, van der Wier G, Diercks GF, et al. IgG-induced clustering of desmogleins 1 and 3 in skin of patients with pemphigus fits with the desmoglein nonassembly depletion hypothesis. Br J Dermatol 2011 ; 165 : 552-62.
PubMed
9) Waschke J, Menendez-Castro C, Bruggeman P, et al. Imaging and force spectroscopy on desmoglein 1 using atomic force microscopy reveal multivalent Ca2+ -dependent, low-affinity trans-interaction. J Membr Biol 2007 ; 216 : 83-92.
PubMed
10) Bektas M, Jolly PS, Berkowitz P, et al. A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysis. J Biol Chem 2013 ; 288 : 9447-56.
 
11) Kamiya K, Aoyama Y, Shirafuji Y, et al. Detection of antibodies against the noncalcium-dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance. Br J Dermatol 2012 ; 167 : 252-61.
 
12) Kamiya K, Aoyama Y, Shirafuji Y, et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. J Dermatol Sci 2013 ; 70 : 190-5.
PubMed
P.71 掲載の参考文献
1) Hertl M, Eming R, Borradori L. Rituximab (antiCD20 monoclonal antibody) -ultimate or first choice in pemphigus? Dermatology 2007 ; 214 : 275-7.
PubMed
2) Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006 ; 116 : 1159-66.
PubMed
3) Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008 ; 128 : 2850-8.
PubMed
4) Colliou N, Picard N, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 2013 ; 5 : 175ra30.
 
5) Lunardon L, Payne AS. Rituximab for autoimmune blistering diseases : recent studies, new insights. G Ital Dermatol Venereol 2012 ; 147 : 269-76.
PubMed
6) Horvath B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012 ; 166 : 405-12.
PubMed
7) Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009 ; 1173 : 683-91.
PubMed
8) Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab : report of 12 cases and a review of the literature. Arch Dermatol 2007 ; 143 : 1033-8.
 
9) Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008 ; 30 : 90-8.
PubMed
10) 宮本樹里亜, 谷川瑛子, 天谷雅行. 天疱瘡 : リツキシマブは有効か? MB Derma 2012 ; 190 : 91-3.
 
P.78 掲載の参考文献
1) Zillikens D. Acquired skin disease of hemidesmosomes. J Dermatol Sci 1999 ; 20 : 134-54.
PubMed
2) Matsumura K, Hashimoto T, Ohata Y, et al. Majority of bullous pemphigoid and herpes gestationis sera react with NC16a domain of the 180kD bullous pemphigoid antigen. Arch Dermatol Res 1996 ; 288 : 507-9.
 
3) Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002 ; 147 : 214-21.
PubMed
4) Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients : a population-based study on incidence. J Am Acad Dermatol 1999 ; 41 : 266-8.
 
5) 稲葉裕, 北村清隆. 類天疱瘡の全国疫学調査の解析. 厚生省特定疾患稀少難治性疾患調査研究班. 昭和63年度研究報告書. 1988. pp61-5.
 
6) 田中達郎, 元木清久, 西隆久, ほか. 佐賀医科大学皮膚科における10年間の天疱瘡群, 類天疱瘡群患者の統計と予後. 西日皮膚 1993 ; 55 : 1092-5.
 
7) 金井塚生世, 杉田泰之, 長谷哲男, ほか. 水疱性類天疱瘡の統計的考察-横浜市立大学皮膚科13年間の観察. 臨皮 1993 ; 47 : 145-8.
 
8) 金森志奈子, 長田智子, 上里博, ほか. 琉球大学皮膚科学教室14年間の水疱性類天疱瘡患者の観察. 西日皮膚 2004 ; 66 : 183-7.
 
9) 北島康雄. 水疱性類天疱瘡ガイドライン. 厚生労働科学研究費補助金難治性皮膚疾患克服研究事業 稀少難治性疾患に関する調査研究 診断治療ガイドライン. 2008. pp15-33.
 
P.82 掲載の参考文献
1) McMillan JR, Akiyama M, Shimizu H. Epidermal basement membrane zone components : ultrastructural distribution and molecular interactions. J Dermatol Sci 2003 ; 31 : 169-77.
PubMed
1) Iwata H, Kitajima Y. Bullous pemphigoid : role of complement and mechanisms for blister formation within the lamina lucida. Exp Dermatol 2013 ; 22 : 381-5.
PubMed
2) Zillikens D, Rose PA, Balding SD, et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997 ; 109 : 573-9.
PubMed
3) Leighty L, Li N, Diaz LA, et al. Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid. Arch Dermatol Res 2007 ; 299 : 417-22.
PubMed
4) Iwata H, Kamio N, Aoyama Y, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009 ; 129 : 919-26.
PubMed
5) Hiroyasu S, Ozawa T, Kobayashi H, et al. Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway. Am J Pathol 2013 ; 182 : 828-40.
 
6) Natsuga K, Nishie W, Shinkuma S, et al. Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner. J Immunol 2012 ; 188 : 5792-9.
 
7) Yayli S, Pelivani N, Beltraminelli H, et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid : a useful clue for diagnosis. Br J Dermatol 2011 ; 165 : 1133-7.
PubMed
8) Nishie W, Lamer S, Schlosser A, et al. Ectodomain shedding generates Neoepitopes on collagen XVII, the major autoantigen for bullous pemphigoid. J Immunol 2010 ; 185 : 4938-47.
PubMed
P.86 掲載の参考文献
1) Hashimoto T, Ishii N, Ohata C, et al. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease. J Pathol 2012 ; 228 : 1-7.
 
2) Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006 ; 41 : 21-30.
PubMed
3) Saleh MA, Ishii K, Kim YJ, et al. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci 2011 ; 62 : 169-75.
PubMed
4) Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002 ; 30 : 224-32.
PubMed
5) Sugi T, Hashimoto T, Hibi T, et al. Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them. J Clin Invest 1989 ; 89 : 1050-5.
 
6) Lee JB, Liu Y, Hashimoto T. Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180. J Dermatol Sci 2003 ; 32 : 59-64.
 
7) Hisamatsu Y, Nishiyama T, Amano S, et al. Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci 2003 ; 33 : 113-9.
PubMed
8) Ishii N, Yoshida M, Hisamatsu Y, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen : study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol 2004 ; 150 : 843-51.
PubMed
9) Dainichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009 ; 106 : 2800-5.
PubMed
10) Schumann H, Baetge J, Tasanen K, et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000 ; 156 : 685-95.
PubMed
P.92 掲載の参考文献
1) Cordel N, Chosidow O, Hellot MF, et al. Neurological disorders in patients with bullous pemphigoid. Dermatology 2007 ; 215 : 187-91.
PubMed
2) Taghipour K, Chi CC, Vincent A, et al. The association of bullous pemphigoid with cerebrovascular disease and dementia : a case-control study. Arch Dermatol 2010 ; 146 : 1251-4.
PubMed
3) Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid : a population-based case-control study. J Invest Dermatol 2011 ; 131 : 631-6.
PubMed
4) Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002 ; 30 : 224-32.
PubMed
5) Nakama T, Ishii N, Ono F, et al. Efficacy of interferon-gamma in patients with refractory bullous pemphigoid. J Dermatol 2007 ; 34 : 737-45.
PubMed
6) Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006 ; 41 : 21-30.
PubMed
7) Messingham KA, Noe MH, Chapman MA, et al. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 2009 ; 346 : 18-25.
PubMed
P.97 掲載の参考文献
1) Lazarova Z, Yee C, Darling T, et al. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996 ; 98 : 1509-18.
PubMed
1) Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid : definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002 ; 138 : 370-9.
PubMed
2) 西脇薫, 岸田功典, 松本由香, ほか. 腫瘍性内科疾患と皮膚 <臨床例> -肺癌を合併したラミニン332型粘膜類天疱瘡. 皮膚病診療 2012 ; 34 : 843-6.
 
3) Hardy KM, Perry HO, Pingree GC, et al. Benign mucous membrane pemphigoid. Arch Dermatol 1971 ; 104 : 467-75.
PubMed
4) Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid : clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore). 2003 ; 82 : 177-86.
PubMed
5) Laskaris G, Sklavounou A, Stratigos J. Bullous pemphigoid, cicatricial pemphigoid, and pemphigus vulgaris. A comparative clinical survey of 278 cases. Oral Surg Oral Med Oral Pathol 1982 ; 54 : 656-62.
PubMed
6) Bedell AJ. Ocular pemphigus : a clinical presentation of kodachromes. Trans Am Ophthalmol Soc 1964 ; 62 : 109-22.
PubMed
7) Bettelheim H, Kraft D, Zehetbauer G. On the so-called ocular pemphigus (pemphigus ocularis, pemphigus conjunctivae). Klin Monbl Augenheilkd 1972 ; 160 : 65-75.
PubMed
8) 福本暁子, 外園千恵. 知っておきたい合併症 (case 15) 粘膜類天疱瘡と眼病変. Visual Dermatology 2013 ; 12 : 170-1.
 
9) Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986 ; 25 : 90-6.
PubMed
10) Bergstrom L. Cicatricial pemphigoid of upper digestive and respiratory tracts. Clin Dermatol 1987 ; 5 : 36-42.
PubMed
11) Lever WF. Pemphigus and pemphigoid. A review of the advances made since 1964. J Am Acad Dermatol 1979 ; 1 : 2-31.
PubMed
12) 松立吉弘, 浦野芳夫, 佐川禎昭, ほか. 膿疱を主病変とした抗BP180型粘膜類天疱瘡の1例. 皮膚臨床 2011 ; 53 : 1011-4.
 
13) Domloge-Hultsch N, Anhalt GJ, Gammon WR, et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol 1994 ; 130 : 1521-9.
PubMed
14) 辻真紀, 白山純実, 今中愛子, ほか. 抗ラミニン332粘膜類天疱瘡の1例-本邦報告例のまとめ. 臨皮 2010 ; 64 : 459-63.
 
15) Taniuchi K, Takata M, Matsui C, et al. Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol 1999 ; 140 : 696-700.
PubMed
16) 橋本隆. 新しい皮膚科検査法 実践マニュアル. 免疫・アレルギー学的検査法 : 水疱症の検査と鑑別. MB Derma 2009 ; 151 (増刊) : 87-97.
 
17) 橋本隆. 瘢痕性類天疱瘡. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2004. pp105-12.
 
18) Nie Z, Hashimoto T. IgA antibodies of cicatricial pemphigoid sera specifically react with C-terminus of BP180. J Invest Dermatol 1999 ; 112 : 254-5.
 
19) Hisamatsu Y, Nishiyama T, Amano S, et al. Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci 2003 ; 33 : 113-9.
PubMed
20) Smith EP, Taylor TB, Meyer LJ, et al. Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. J Invest Dermatol 1993 ; 101 : 619-23.
PubMed
21) Tyagi S, Bhol K, Natarajan K, et al. Ocular cicatricial pemphigoid antigen : partial sequence and biochemical characterization. Proc Natl Acad Sci U S A 1996 ; 93 : 14714-9.
PubMed
P.105 掲載の参考文献
1) Matsumura Y, Hamanaka H, Horiguchi Y, et al. Epidermolysis bullosa acquisita (EBA) with nonclassical distribution of eruptions. J Dermatol 1993 ; 20 : 159-63.
PubMed
2) Marzano AV, Cozzani E, Fanoni D, et al. Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies : an Italian multicentre study. Br J Dermatol 2013 ; 168 : 80-4.
PubMed
3) Sitaru C, Mihai S, Otto C, et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005 ; 115 : 870-8.
PubMed
P.109 掲載の参考文献
1) Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid : recommendations by an international panel of experts. J Am Acad Dermatol 2012 ; 66 : 479-85.
PubMed
2) 北島康雄. 水疱性類天疱瘡ガイドライン. 厚生労働科学研究費補助金難治性皮膚疾患克服研究事業 稀少難治性疾患に関する調査研究 診断治療ガイドライン. 2008. pp15-33.
 
3) 名嘉眞武国, 橋本隆. 水疱症-高齢者に多い皮膚疾患の診断と治療の注意点. 老年医学 2012 ; 50 : 825-30.
 
4) Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 1986 ; 122 : 670-4.
PubMed
5) 橋本隆. 類天疱瘡のテトラサイクリン療法. 皮膚臨床 1995 ; 37 : 1063-6.
 
6) Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemhoigoid : possible anti-inflammatory effects. J Am Acad Dermatol 1982 ; 7 : 504-10.
PubMed
7) Schmidt E, Kraensel R, Goebeler M, et al. Treatment of bullous pemohigoid with dapsone, methylprednisolone, and topical clobetasol propionate : a retrospective study of 62 cases. Cutis 2005 ; 76 : 205-9.
PubMed
8) Hornschuh B, Hamm H, Weber S, at al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997 ; 36 : 101-3.
 
9) Joly P, Roujeau JC, Benichou J, et al. A comparison of oral topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002 ; 346 : 321-7.
PubMed
10) Chan LS, Ahmed R, Anhalt GJ, et al. Mucous membrane pemphigoid : definition, diagnosticcriteria, pathogenic factors, medical treatment and prognostic factors. Arch Dermatol 2002 ; 138 : 370-9.
 
11) Taniuchi K, Tanaka M, Matsui C, et al. Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol 1999 ; 140 : 696-700.
 
P.115 掲載の参考文献
1) Tsuruta D, Kobayashi H, Imanishi H, et al. Laminin-332-integrin interaction : a target for cancer therapy? Curr Med Chem 2008 ; 15 : 1968-75.
PubMed
1) Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol 2004 ; 20 : 255-84.
PubMed
2) Carter WG, Kaur P, Gil SG, et al. Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes : relation to hemidesmosomes. J Cell Biol 1990 ; 111 : 3141-54.
 
2) Sugawara K, Tsuruta D, Ishii M, et al. Laminin-332 and -511 in normal skin and skin disease. Exp Dermatol 2008 ; 17 : 473-80.
 
3) Tsuruta D, Hashimoto T, Hamill KJ, et al. Hemidesmosomes and focal contact proteins : functions and cross-talk in keratinocytes, bullous diseases and wound healing. J Cell Sci 2011 ; 62 : 1-7.
 
4) Ozawa T, Tsuruta D, Jones JC, et al. Dynamic relationship of focal contacts and hemidesmosome protein complexes in live cells. J Invest Dermatol 2010 ; 130 : 1624-35.
 
5) Hamill KJ, Hopkinson SB, DeBiase P, et al. BPAG1e maintains keratinocyte polarity through beta4 integrin-mediated modulation of Rac1 and cofilin activities. Mol Biol Cell 2009 ; 20 : 2954-62.
PubMed
6) Tsuruta D, Hopkinson SB, Jones JC. Hemidesmosome protein dynamics in live epithelial cells. Cell Motil Cytoskeleton 2003 ; 54 : 122-34.
PubMed
7) Veitch DP, Nokelainen P, McGowan KA, et al. Mammalian tolloid metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin. J Biol Chem 2003 ; 278 : 15661-8.
PubMed
8) Owaribe K, Kartenbeck J, Stumpp S, et al. The hemidesmosomal plaque I. Characterization of a major constituent protein as a differentiation marker for certain forms of epithelia. Differentiation 1990 ; 45 : 207-20.
 
9) Goldfinger LE, Stack MS, Jones JC. Processing of laminin-5 and its functional consequences : role of plasmin and tissue-type plasminogen activator. J Cell Biol 1998 ; 141 : 255-65.
PubMed
10) Giannelli G, Antonaci S. Biological and clinical relevance of laminin-5 in cancer. Clin Exp Metastasis 2000 ; 18 : 439-43.
PubMed
11) Katayama M, Sanzen N, Funakoshi A, et al. Laminin gamma2-chain fragment in the circulation : a prognostic indicator of epithelial tumor invasion. Cancer Res 2003 ; 63 : 222-9.
PubMed
P.120 掲載の参考文献
1) Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993 ; 92 : 2480-8.
PubMed
2) Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995 ; 95 : 1539-44.
PubMed
3) Nishie W, Sawamura D, Goto M, et al. Humanization of autoantigen. Nat Med 2007 ; 13 : 378-83.
PubMed
4) Liu Z, Sui W, Zhao M, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008 ; 31 : 331-8.
 
5) Li Q, Ujiie H, Shibaki A, et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010 ; 185 : 7746-55.
 
6) Natsuga K, Nishie W, Shinkuma S, et al. Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner. J Immunol 2012 ; 188 : 5792-9.
 
7) Iwata H, Kamio N, Aoyama Y, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009 ; 129 : 919-26.
PubMed
8) Ujiie H, Shibaki A, Nishie W, et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010 ; 184 : 2166-74.
PubMed
9) Hirose M, Recke A, Beckmann T, et al. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 2011 ; 187 : 1176-83.
PubMed
P.125 掲載の参考文献
1) Jablonska S, Chorzelski TP, Beutner EH, et al. Dermatitis herpetiformis and bullous pemphigoid. Intermediate and mixed forms. Arch Dermatol 1976 ; 112 : 45-8.
PubMed
2) Chorzelski TP, Jablonska S. IgA linear dermatosis of childhood (chronic bullous disease of childhood). Br J Dermatol 1979 ; 101 : 535-42.
PubMed
3) Pothupitiya GM, Wojnarowska F, Bhogal BS, et al. Distribution of the antigen in adult linear IgA disease and chronic bullous dermatosis of childhood suggests that it is a single and unique antigen. Br J Dermatol 1988 ; 118 : 175-82.
PubMed
4) Nanda A, Dvorak R, Al-Sabah H, et al. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol 2004 ; 43 : 876-81.
PubMed
5) Nanda A, Dvorak R, Al-Sabah H, et al. Linear IgA bullous disease of childhood : an experience from Kuwait. Pediatr Dermatol 2006 ; 23 : 443-7.
PubMed
6) Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995 ; 131 : 957-8.
 
7) Baden LA, Apovian C, Imber MJ, et al. Vancomycin-induced linear IgA bullous dermatosis. Arch Dermatol 1988 ; 124 : 1186-8.
PubMed
8) Plunkett RW, Chiarello SE, Beutner EH. Linear IgA bullous dermatosis in one of two piroxicam-induced eruptions : a distinct direct immunofluorescence trend revealed by the literature. J Am Acad Dermatol 2001 ; 45 : 691-6.
PubMed
9) Zone JJ, Taylor TB, Kadunce DP, et al. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990 ; 85 : 812-20.
PubMed
10) Marinkovich MP, Taylor TB, Keene DR, et al. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996 ; 106 : 734-8.
PubMed
11) Hirako Y, Usukura J, Uematsu J, et al. Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. J Biol Chem 1998 ; 273 : 9711-7.
PubMed
12) Zone JJ, Taylor TB, Meyer LJ, et al. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 1998 ; 110 : 207-10.
PubMed
13) Vodegel RM, de Jong MC, Pas HH, et al. IgA-mediated epidermolysis bullosa acquisita : two cases and review of the literature. J Am Acad Dermatol 2002 ; 47 : 919-25.
PubMed
14) Usmani N, Baxter KF, Child JA, et al. Linear IgA disease in association with chronic lymphocytic leukaemia. Br J Dermatol 2004 ; 151 : 710-1.
PubMed
15) Rodenas JM, Herranz MT, Tercedor J, et al. Linear IgA disease in a patient with bladder carcinoma. Br J Dermatol 1997 ; 136 : 257-9.
 
16) Walker SL, Banerjee P, Harland CC, et al. Remission of linear IgA disease associated with ulcerative colitis following panproclocolectomy. Br J Dermatol 2000 ; 143 : 1341-2.
PubMed
17) Horiguchi Y, Ikoma A, Sakai R, et al. Linear IgA dermatosis : report of an infantile case and analysis of 213 cases in Japan. J Dermatol 2008 ; 35 : 737-43.
PubMed
18) Benbenisty KM, Bowman PH, Davis LS. Localized linear IgA disease responding to colchicines. Int J Dermatol 2002 ; 41 : 56-8.
PubMed
19) Young HS, Coulson IH. Linear IgA disease : successful treatment with cyclosporine. Br J Dermatol 2000 ; 143 : 204-5.
PubMed
P.130 掲載の参考文献
1) Ohata C, Ishii N, Hamada T, et al. Distinct characteristics in Japanese dermatitis herpetiformis : a review of all 91 Japanese patients over the last 35 years. Clin Dev Immunol 2012 ; 2012 : 562168.
PubMed
2) Fry L. Dermatitis herpetiformis : problems, progress and prospects. Eur J Dermatol 2002 ; 12 : 523-31.
PubMed
3) Marietta E, Black K, Camilleri M, et al. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 2004 ; 114 : 1090-7.
 
4) Alonso-Llamazares J, Gibson LE, Rogers RS 3rd. Clinical, pathologic, and immunopathologic feature of dermatitis herpetiformis : review of the Mayo Clinic experience. Int J dermatol 2007 ; 46 : 910-9.
 
5) 藤本亘. Duhring疱疹状皮膚炎. 玉置邦彦, ほか編. 最新皮膚科学大系 6. 水疱症 膿疱症. 東京 : 中山書店 ; 2002. pp122-30.
 
6) 藤城幹山, 大久保ゆかり, 三橋善比古, ほか. 乾癬の抗TNF-α抗体療法中に発症したDuhring疱疹状皮膚炎. 皮膚病診療 2010 ; 32 : 1211-4.
 
7) 長谷川豪, 斎藤祐尚. トランスグルタミナーゼの多機能性. 蛋白核酸酵素 2004 ; 49 : 642-8.
 
8) Sardy M, Karpati S, Merkl B, et al. Epidermal Transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002 ; 195 : 747-57.
PubMed
9) Rose C, Armbruster FP, Ruppert J, et al. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermaol 2009 ; 61 : 39-43.
PubMed
10) Asano Y, Makino T, Ishida W, et al. Detection of antibodies to epidermal transglutaminase but not tissue transglutaminase in Japanese patients with dermatitis herpetiformis. Br J Dermatol 2011 ; 164 : 883-4.
 
11) 近藤美幾, 川原繁, 竹原和彦, ほか. ジューリング疱疹状皮膚炎の1例. 皮膚臨床 2003 ; 45 : 875-7.
 
12) 川名誠司. 共焦点レーザー走査顕微鏡の皮膚科学への応用. 臨皮 1994 ; 48 : 119-22.
 
13) Caproni M, Antiga E, Melani L, et al. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. Eur Acad Dermatol Venereol 2009 ; 23 : 633-8.
PubMed
14) Lewis NR, Logan RF, Hubbard RB, et al. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis : a cohort study. Aliment Pharmacol Ther 2008 ; 27 : 1140-7.
PubMed
15) 加倉井真樹, 出光俊郎. 線状IgA水疱症, 疱疹状皮膚炎の診断と治療. MB Derma 2008 ; 137 : 61-5.
 
16) 坂本久美子, 大圃詩子, 原弘之, ほか. Duhring疱疹状皮膚炎. 皮膚病診療 2008 ; 30 : 1131-4.
 
P.136 掲載の参考文献
1) Olivry T, Chan LS. Autoimmune blistering dermatoses in domestic animals. Clin Dermatol 2001 ; 19 : 750-60.
 
2) Stannard AA, Gribble DH, Baker BB. A mucocutaneous disease in the dog, resembling pemphigus vulgaris in man. J Am Vet Med Assoc 1975 ; 166 : 575-82.
 
3) Hurvitz AI, Feldman E. A disease in dogs resembling human pemphigus vulgaris : case reports. J Am Vet Med Assoc 1975 ; 166 : 585-90.
 
4) Nishifuji K, Amagai M, Ota T, et al. Cloning of canine desmoglein 3 and immunoreactivity of serum antibodies in human and canine pemphigus vulgaris with its extracellular domains. J Dermatol Sci 2003 ; 32 : 181-91.
PubMed
5) Olivry T, Joubeh S, Dunston SM, et al. Desmoglein-3 is a taget antigen in spontaneous canine pemphigus vulgaris. Exp Dermatol 2003 ; 12 : 198-203.
 
6) Nishifuji K, Olivry T, Ishii K, et al. IgG autoantibodies directed against desmoglein 3 cause dissociation of keratinocytes in canine pemphigus vulgaris and paraneoplastic pemphigus. Vet Immunol Immunopathol 2007 ; 117 : 209-21.
PubMed
7) Nishifuji K, Tamura K, Konno H, et al. Development of an enzyme-linked immunosorbent assay for detection of circulating IgG autoantibodies against canine desmoglein 3 in dogs with pemphigus. Vet Dermatol 2009 ; 20 : 331-7.
PubMed
8) Winfield LD, White SD, Affolter VK, et al. Pemphigus vulgaris in a Welsh pony stallion : case report and demonstration of antidesmoglein autoantibodies. Vet Dermatol 2013 ; 24 : 269-e60.
 
9) Lemmens P, de Bruin A, de Meulemeester J, et al. Paraneoplastic pemphigus in a dog. Vet Dermatol 1998 ; 9 : 127-34.
 
10) Elmore SA, Basseches J, Anhalt GJ, et al. Paraneoplastic pemphigus in a dog with splenic sarcoma. Vet Pathol 2005 ; 42 : 88-91.
 
11) de Bruin A, Muller E, Wyder M, et al. Periplakin and envoplakin are target antigens in canine and human paraneoplastic pemphigus. J Am Acad Dermatol 1999 ; 40 : 682-5.
PubMed
12) Halliwell REW, Goldschmidt M. Pemphigus foliaceus in the canine : a case report and discussion. J Am Anim Hosp Assoc 1977 ; 13 : 431.
 
13) Iyori K, Hisatsune J, Kawakami T, et al. Identification of a novel Staphylococcus pseudintermedius exfoliative toxin gene and its prevalence in isolates from canines with pyoderma and healthy dogs. FEMS Microbiol Lett 2010 ; 312 : 169-75.
PubMed
14) Iyori K, Futagawa-Saito K, Hisatsune J, et al. Staphylococcus pseudintermedius exfoliative toxin EXI selectively digests canine desmoglein 1 and causes subcorneal clefts in canine epidermis. Vet Dermatol 2011 ; 22 : 319-26.
PubMed
15) Bizikova P, Dean GA, Hashimoto T, et al. Cloning and establishment of canine desmocollin-1 as a major autoantigen in canine pemphigus foliaceus. Vet Immunol Immunopathol 2012 ; 149 : 197-207.
 
16) Olivry T, LaVoy A, Dunston SM, et al. Desmoglein-1 is a minor autoantigen in dogs with pemphigus foliaceus. Vet Immunol Immunopathol 2006 ; 110 : 245-55.
PubMed
17) Iwasaki T, Olivry T, Lapier JC, et al. Canine bullous pemphigoid (BP) : identification of the 180-kDa canine BP antigen by circulating autoantibodies. Vet Pathol 1995 ; 32 : 387-93.
 
18) Xu L, O'Toole EA, Olivry T, et al. Molecular cloning of canine bullous pemphigoid antigen 2 cDNA and immunomapping of NC16A domain by canine bullous pemphigoid autoantibodies. Biochim Biophys Acta 2000 ; 1500 : 97-107.
 
19) Olivry T, Bizikova P, Dunston SM, et al. Clinical and immunological heterogeneity of canine subepidermal blistering dermatoses withanti-laminin-332 (laminin-5) auto-antibodies. Vet Dermatol 2010 ; 21 : 345-57.
 

II 先天性水疱症

P.144 掲載の参考文献
1) 清水宏. あたらしい皮膚科学. 第2版. 東京 : 中山書店 ; 2011. pp222-32.
 
2) Bruckner-Tuderman L, McGrath JA, Robinson EC, et al. Animal models of epidermolysis bullosa : update 2010. J Invest Dermatol 2010 ; 130 : 1485-8.
PubMed
3) Natsuga K. Epidermolysis bullosa simplex. In : Oiso N, editor. Current Genetics in Dermatology. Rijeka : InTech ; 2013. pp31-46. http://www.intechopen.com/articles/show/title/epidermolysis-bullosa-simplex.
 
4) Natsuga K, Shinkuma S, Nishie W, et al. Animal models of epidermolysis bullosa. Dermatol Clin 2010 ; 28 : 137-42.
PubMed
5) Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
6) Fine JD, Bauer EA, Briggaman RA, et al. Revised clinical and laboratory criteria for subtypes of inherited epidermolysis bullosa. A consensus report by the Subcommittee on Diagnosis and Classification of the National Epidermolysis Bullosa Registry. J Am Acad Dermatol 1991 ; 24 : 119-35.
PubMed
7) Fine JD, Eady RA, Bauer EA, et al. Revised classification system for inherited epidermolysis bullosa : report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol 2000 ; 42 : 1051-66.
PubMed
8) Pigors M, Kiritsi D, Krumpelmann S, et al. Lack of plakoglobin leads to lethal congenital epidermolysis bullosa : a novel clinico-genetic entity. Hum Mol Genet 2011 ; 20 : 1811-9.
PubMed
9) Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010 ; 130 : 1551-7.
PubMed
10) Has C, Sparta G, Kiritsi D, et al. Integrin alpha3 mutations with kidney, lung, and skin disease. N Engl J Med 2012 ; 366 : 1508-14.
PubMed
11) Koss-Harnes D, Hoyheim B, Anton-Lamprecht I, et al. A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna : two identical de novo mutations. J Invest Dermatol 2002 ; 118 : 87-93.
PubMed
12) Kiritsi D, Pigors M, Tantcheva-Poor I, et al. Epidermolysis Bullosa Simplex Ogna Revisited. J Invest Dermatol 2013 ; 133 : 270-3.
PubMed
13) Natsuga K, Nishie W, Shinkuma S, et al. Plectin deficiency leads to both muscular dystrophy and pyloric atresia in epidermolysis bullosa simplex. Hum Mutat 2010 ; 31 : E1687-98.
PubMed
14) Natsuga K, Nishie W, Arita K, et al. Complete paternal isodisomy of chromosome 17 in junctional epidermolysis bullosa with pyloric atresia. J Invest Dermatol 2010 ; 130 : 2671-4.
PubMed
15) Szeverenyi I, Cassidy AJ, Chung CW, et al. The Human Intermediate Filament Database : comprehensive information on a gene family involved in many human diseases. Hum Mutat 2008 ; 29 : 351-60.
PubMed
16) van den Akker PC, Jonkman MF, Rengaw T, et al. The international dystrophic epidermolysis bullosa patient registry : an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat 2011 ; 32 : 1100-7.
PubMed
17) Thusberg J, Olatubosun A, Vihinen M. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 2011 ; 32 : 358-68.
PubMed
18) Natsuga K, Nishie W, Smith BJ, et al. Consequences of two different amino-acid substitutions at the same codon in KRT14 indicate definitive roles of structural distortion in epidermolysis bullosa simplex pathogenesis. J Invest Dermatol 2011 ; 131 : 1869-76.
PubMed
19) Fujita Y, Abe R, Inokuma D, et al. Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. Proc Natl Acad Sci U S A 2010 ; 107 : 14345-50.
PubMed
20) Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010 ; 363 : 629-39.
PubMed
P.148 掲載の参考文献
1) Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on diagnosis and classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
2) 新熊悟, 清水宏. 表皮水疱症 : 病態と診断. 日皮会誌 2011 ; 121 : 127-33.
 
3) Coulombe PA, Hutton ME, Letai A, et al. Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients : genetic and functional analyses. Cell 1991 ; 66 : 1301-11.
PubMed
4) Lane EB, Rugg EL, Navsaria H, et al. A mutation in the conserved helix termination peptide of keratin 5 in hereditary skin blistering. Nature 1992 ; 356 : 244-6.
 
5) Huber M, Floeth M, Borradori L, et al. Deletion of the cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex. J Invest Dermatol 2002 ; 118 : 185-92.
PubMed
6) Jonkman MF, Pas HH, Nijenhuis M, et al. Deletion of a cytoplasmic domain of integrin beta4 causes epidermolysis bullosa simplex. J Invest Dermatol 2002 ; 119 : 1275-81.
PubMed
7) Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010 ; 130 : 1551-7.
PubMed
8) McGrath JA, McMillan JR, Shemanko CS, et al. Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome. Nat Genet 1997 ; 17 : 240-4.
PubMed
9) Jonkman MF, Pasmooij AM, Pasmans SG, et al. Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am J Hum Genet 2005 ; 77 : 653-60.
PubMed
10) Herrmann H, Strelkov SV, Burkhard P, et al. Intermediate filaments : primary determinants of cell architecture and plasticity. J Clin Invest 2009 ; 119 : 1772-83.
PubMed
11) Batta K, Rugg EL, Wilson NJ, et al. A keratin 14 'knockout' mutation in recessive epidermolysis bullosa simplex resulting in less severe disease. Br J Dermatol 2000 ; 143 : 621-7.
PubMed
12) Szeverenyi I, Cassidy AJ, Chung CW, et al. The Human Intermediate Filament Database : comprehensive information on a gene family involved in many human diseases. Hum Mutat 2008 ; 29 : 351-60.
PubMed
13) Bolling MC, Lemmink HH, Jansen GH, et al. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75 % of the patients. Br J Dermatol 2011 ; 164 : 637-44.
 
14) Natsuga K, Nishie W, Akiyama M, et al. Plectin expression patterns determine two distinct subtypes of epidermolysis bullosa simplex. Hum Mutat 2010 ; 31 : 308-16.
PubMed
15) Natsuga K, Nishie W, Shinkuma S, et al. Plectin deficiency leads to both muscular dystrophy and pyloric atresia in epidermolysis bullosa simplex. Hum Mutat 2010 ; 31 : E1687-98.
PubMed
16) Kiritsi D, Pigors M, Tantcheva-Poor I, et al. Epidermolysis bullosa simplex ogna revisited. J Invest Dermatol 2013 ; 133 : 270-3.
PubMed
17) 清水宏. あたらしい皮膚科学. 第2版. 東京 : 中山書店 ; 2011.
 
18) Shinkuma S, McMillan JR, Shimizu H. Ultrastructure and molecular pathogenesis of epidermolysis bullosa. Clin Dermatol 2011 ; 29 : 412-9.
PubMed
P.156 掲載の参考文献
1) Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
1) Nakano A, Pfender E, Pulkkinen L, et al. Herlitz junctional epidermolysis bullosa : novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. J Invest Dermtol 2000 ; 115 : 493-8.
 
2) Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006 ; 12 : 1397-402.
PubMed
3) Pulkkinen L, Rouan F, Bruckner-Tuderman L, et al. Novel ITGB4 mutations in lethal and nonlethal variants of epidermolysis bullosa with pyloric atresia : missense versus nonsense. Am J Hum Genet 1998 ; 63 : 1376-87.
PubMed
P.163 掲載の参考文献
1) Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
2) Christiano AM, Greenspan DS, Hoffman GG, et al. A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nat Genet 1993 ; 4 : 62-6.
PubMed
3) Hilal L, Rochat A, Duquesnoy P, et al. A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa. Nat Genet 1993 ; 5 : 287-93.
PubMed
4) Pulkkinen L, Uitto J. Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol 1999 ; 18 : 29-42.
PubMed
5) Sawamura D, Goto M, Yasukawa K, et al. Genetic studies of 20 Japanese families of dystrophic epidermolysis bullosa. J Hum Genet 2005 ; 50 : 543-6.
PubMed
6) Wanger JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2011 ; 363 : 629-39.
 
P.168 掲載の参考文献
1) McGrath JA, McMillan JR, Shemanko CS, et al. Mutations in the plakophilin 1 gene result in ectodermal dysplasia/skin fragility syndrome. Nat Genet 1997 ; 17 : 240-4.
PubMed
2) Whittock NV, Wan H, Morley SM, et al. Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol 2002 ; 118 : 232-8.
PubMed
3) Fine JD, Eady RAJ, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
4) Olivry T, Linder KE, Wang P, et al. Deficient plakophilin-1 expression due to a mutation in PKP1 causes ectodermal dysplasia-skin fragility syndrome in Chesapeake Bay retriever dogs. PLoS ONE 2012 ; 7 : e32072.
PubMed
5) Cabral RM, Liu L, Hogan C, et al. Homozygous mutations in the 5' region of the JUP gene result in cutaneous disease but normal heart development in children. J Invest Dermatol 2010 ; 130 : 1543-50.
 
6) Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013 ; 45 : 1244-8.
PubMed
7) Hamada T, South AP, Mitsuhashi Y, et al. Genotype-phenotype correlation in skin fragility-ectodermal dysplasia syndrome resulting from mutations in plakophilin 1. Exp Dermatol 2002 ; 11 : 107-14.
PubMed
8) Tanaka A, Lai-Cheong JE, Cafe MEM, et al. Novel truncating mutations in PKP1 and DSP cause similar skin phenotypes in two Brazilian families. Br J Dermatol 2009 ; 160 : 692-7.
PubMed
9) Jonkman MF, Pasmooij AMG, Pasmans SGMA, et al. Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am J Hum Genet 2005 ; 77 : 653-60.
PubMed
10) McGrath JA, Mellerio JE. Ectodermal dysplasia-skin fragility syndrome. Dermatologic Clinics 2010 ; 28 : 125-9.
PubMed
P.175 掲載の参考文献
1) Kiritsi D, He Y, Pasmooij AM, et al. Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination. J Clin Invest 2012 ; 122 : 1742-6.
 
1) Kindler T. Congenital poikiloderma with traumatic bulla formation and progressive cutaneous atrophy. Br J Dermatol 1954 ; 66 : 104-11.
PubMed
2) Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
2) Lai-Cheong JE, Moss C, Parsons M, et al. Revertant mosaicism in Kindler syndrome. J Invest Dermatol 2012 ; 132 : 730-2.
PubMed
3) Jobard F, Bouadjar B, Caux F, et al. Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum Mol Genet 2003 ; 12 : 925-35.
 
4) Siegel DH, Ashton GH, Penagos HG, et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet 2003 ; 73 : 174-87.
PubMed
5) Larjava H, Plow EF, Wu C. Kindlins : essential regulators of integrin signalling and cell-matrix adhesion. EMBO Rep 2008 ; 9 : 1203-8.
PubMed
6) Has C, Castiglia D, del Rio M, et al. Kindler syndrome : extension of FERMT1 mutational spectrum and natural history. Hum Mutat 2011 ; 32 : 1204-12.
PubMed
7) Shimizu H, Sato M, Ban M, et al. Immunohistochemical, ultrastructural, and molecular features of Kindler syndrome distinguish it from dystrophic epidermolysis bullosa. Arch Dermatol 1997 ; 133 : 1111-7.
PubMed
8) Cardin-Langlois E, Hanna D, St-Amant M, et al. Invasive squamous cell carcinoma of the hand in a patient with Kindler syndrome : case report and literature review. Can J Plast Surg 2010 ; 18 : e41-3.
 
P.180 掲載の参考文献
1) Kostaki D, Castillo JC, Ruzicka T, et al. Longitudinal leuconychia striata : Is it a common sign in Hailey-Hailey and Darier disease? J Eur Acad Dermatol Venereol 2014 ; 28 : 126-7.
PubMed
1) Hailey H, Hailey H. Familial benign chronic pemphigus. Arch Dermatol Syph 1939 ; 39 : 679-85.
 
2) Hu Z, Bonifas JM, Beech J, et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet 2000 ; 24 : 61-5.
PubMed
3) Yakis G, Csato M, Kemeny L, et al. Hailey-Hailey disease with acrokeratosis verruciformis Hopf. Acta Derm Venereol 1996 ; 76 : 157.
PubMed
4) Bruge SM. Hailey-Hailey disease : the clinical features, response to treatment and prognosis. Br J Dermatol 1992 ; 126 : 275-82.
 
5) Aoki T, Hashimoto H, Koseki S, et al. 1alpha,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in in vivo and in vitro. Br J Dermatol 1998 ; 139 : 897-901.
PubMed
6) Mashiko M, Akiyama M, Tsuji-Abe Y, et al. Bacterial infection-induced generalized Hailey-Hailey disease successfully treated by etretinate. Clin Exp Dermatol 2006 ; 31 : 57-9.
PubMed
7) Berth-Jones J, Smith SG, Graham-Brown RA. Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporine. Clin Exp Dermatol 1995 ; 20 : 70-2.
PubMed
8) Fairris G, White J, Leppard B, et al. Methotrexate for intractable benign familial chronic pemphigus. Br J Dermatol 1986 ; 115 : 640.
PubMed
9) Collet Villette AM, Richard MA, Fourquet F, et al. Treatment of Hailey-Hailey disease with carbon dioxide laser vaporization. Ann Dermatol Venereol 2005 ; 132 : 637-40.
PubMed
10) Ruiz-Rodriguez R, Alvarez JG, Jaen P, et al. Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 2002 ; 47 : 740-2.
PubMed
11) Awadalla F, Rosenbach A. Effective treatment of Hailey-Hailey disease with a long-pulsed (5 ms) alexandrite laser. J Cosmet Laser Ther 2011 ; 13 : 191-2.
PubMed
P.185 掲載の参考文献
1) 上田恵一, 八町裕宏. ダリエ病とヘイリーヘイリー病. 石橋康正, 編. 皮膚科MOOK 15. 角化異常症. 東京 : 金原出版 ; 1989. pp121-31.
 
2) Munro CS. The phenotype of Derier's disease : penetrance and expressivity in adults and children. Br J Dermatol 1992 ; 127 : 126-30.
 
3) Sakuntabhai A, Ruiz-Perz VL, Cater S, et al. Mutation in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999 ; 21 : 271-7.
 
4) 池田志斈. Darier病. 玉置邦彦, ほか編. 最新皮膚科学大系 7. 角化異常性疾患. 東京 : 中山書店 ; 2002. pp160-7.
 
5) 高木敦, 水野優起, 春名邦隆, ほか. 角化異常症の遺伝子診断の実際. MB Derma 2009 ; 151 : 157-66.
 
6) English JC 3rd, Browne J, Halbach DP. Effective treatment of localized Darier's disease with adapalene 0.1 % gel. Cutis 1999 ; 63 : 227-30.
 
7) Larbre B, Nicolas JF, Frappaz A, et al. Cyclosporine and Darier's disease. Ann Dermatol Venereol 1993 ; 120 : 310-31.
PubMed
8) Bigard X, Sanchez H, Zoll J, et al. Calsineurin co-regulates contractile and metabolic components of slow muscle phenotype. J Bio Chem 2000 ; 275 : 19653-60.
 
9) Speight EL. Vesiculobullous Darier's disease responsive to oral prednisolone. Br J Dermatol 1998 ; 139 : 934-5.
PubMed
10) 高橋健造. Darier病の治療薬の探索と病態の理解. 皮膚病診療 2012 ; 34 : 305-10.
 
11) Mayuzumi N, Ikeda S, Kawada H, et al. Effects of UV-B irradiation, pro-inflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1. Br J Dermatol 2005 ; 152 : 697-701.
 
12) Kamijo M, Nishiyama C, Takagi A, et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERCA2 in keratinocytes : possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease. Br J Dermatol 2012 ; 166 : 1017-22.
PubMed
P.190 掲載の参考文献
1) Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB) : report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008 ; 58 : 931-50.
 
2) Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes : formation of keratinocyte colonies from single cells. Cell 1975 ; 6 : 331-43.
PubMed
3) O'Connor NE, Mulliken JB, Banls-Schegel S, et al. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet 1981 ; 1 : 75-8.
 
4) 熊谷憲夫, 大島秀夫, 松崎恭一, ほか. 培養表皮の皮膚疾患への応用. 皮膚臨床 1995 ; 37 : 1133-43.
 
5) Boyce ST, Ham RG. Calcium-regulated differentiation of normal human epidermal keratinocytes in chemidal defined clonal culture and serum-free serial culture. J Invest Dermatol 1983 ; 81 (1 suppl) : 33s-40s.
 
6) Pittelkow MR, Scott RE. New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns. Mayo Clin Proc 1986 ; 61 : 771-7.
PubMed
7) 橋本公二. 培養表皮シート移植. 皮膚病診療 1995 ; 17 : 432-6.
 
8) 白方裕司, 橋本公二. 培養皮膚の臨床応用. 日皮会誌 1999 ; 109 : 1301-7.
 
9) Carter DM, Lin AN, Varghese MC, et al. Treatment of junctional epidermolysis bullosa with epidermal autografts. J Am Acad Dermatol 1987 ; 17 : 246-50.
PubMed
10) Eisenberg M, Llewellyn DM, Moran K, et al. Successful engraftment of cultured human epidermal allograft in a child with recessive dystrophic epidermolysis bullosa. Med J Aust 1987 ; 147 : 520-1.
 
11) McGrath JA, Schofield OM, Ishida-Yamamoto A, et al. Cultured keratinocyte allografts and wound healing in severe dystrophic epidermolysis bullosa. J Am Acad Dermatol 1993 ; 29 : 407-19.
PubMed
12) Natsuga K, Sawamura D, Goto M, et al. Response of intractable skin ulcers in recessive dystrophic epidermolysis bullosa patients to an allogeneic cultured dermal substitute. Acta Derm Venereol 2010 ; 90 : 165-9.
 
13) Falabella AF, Valencia IC, Eaglstein WH, et al. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 2000 ; 136 : 1225-30.
PubMed
14) 井家益和. 再生医療製品として開発された自家培養表皮の有効性と安全性の評価. 日本香粧品学会誌 2010 ; 34 : 126-32.
 
15) Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008 ; 128 : 2179-89.
PubMed
16) Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 2010 ; 12 : 429-31.
PubMed
17) Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010 ; 363 : 629-39.
PubMed
18) Tolar J, Xia L, Riddle MJ, et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2011 ; 131 : 848-56.
PubMed
P.196 掲載の参考文献
1) Chino T, Tamai K, Yamazaki T, et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 2008 ; 173 : 803-14.
 
2) Fujita Y, Abe R, Inokuma D, et al. Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. Proc Natl Acad Sci U S A 2010 ; 107 : 14345-50.
PubMed
3) Tamai K, Yamazaki T, Chino T, et al. PDGFRα-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A 2011 ; 108 : 6609-14.
 
4) Takashima Y, Era T, Nakao K, et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 2007 ; 129 : 1377-88.
PubMed
5) Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010 ; 363 : 629-39.
PubMed
6) Conget P, Rodrguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 2010 ; 12 : 429-31.
 
7) Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997 ; 276 : 71-4.
PubMed
8) Alexeev V, Uitto J, Igoucheva O. Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. Cytotherapy 2011 ; 13 : 30-45.
PubMed
9) Inokuma D, Abe R, Fujita Y, et al. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. Stem Cells 2006 ; 30 : 2810-6.
 
10) Itoh M, Kiuru M, Cairo MS, et al. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci U S A 2011 ; 108 : 8797-802.
PubMed
11) Osborn MJ, Starker CG, McElroy AN, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther 2013 ; 21 : 1151-9.
PubMed
12) Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006 ; 12 : 1397-402.
PubMed

III その他の水疱性皮膚疾患

P.202 掲載の参考文献
1) Watanabe R, Watanabe H, Iijima M, et al. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN). Eur J Dermatol 2011 ; 21 : 889-94.
PubMed
2) Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008 ; 14 : 1343-50.
PubMed
3) Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009 ; 151 : 514-5.
PubMed
4) Fujita Y, Yoshioka N, Abe R, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 2011 ; 65 : 65-8.
PubMed
5) 渡辺秀晃, 末木博彦, 飯島正文. Stevens-Johnson症候群. 塩原哲夫, ほか編. 皮膚科診療プラクティス 19. 薬疹を極める. 東京 : 文光堂 ; 2006. pp43-8.
 
6) Nakajima S, Watanabe H, Tohyama M, et al. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 2011 ; 147 : 1110-2.
PubMed
7) Chung WH, Hung SI, Hong HS, et al. Medical genetics : a marker for Stevens-Johnson syndrome. Nature 2004 ; 428 : 486.
PubMed
8) Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005 ; 102 : 4134-9.
PubMed
9) Pereira FA, Mudgil AV, Rosmarin DM, et al. Toxic epidermal necrolysis. J Am Acad Dermatol 2007 ; 56 : 181-200.
PubMed
10) Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis : a review of the literature. Ann Allergy Asthma Immunol 2005 ; 94 : 419-36.
PubMed
11) 相原道子, 狩野葉子, 飯島正文, ほか. Stevens-Johnson症候群および中毒性表皮壊死症 (TEN) の治療方針-平成20年度厚生労働科学研究費補助金 (難治性疾患克服研究事業) 急性多形滲出性紅斑に関する治療指針2009の解説. 日皮会誌 2009 ; 119 ; 2157.
 
12) Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome : a total series of 67 cases. Allergy Asthma Proc 2000 ; 21 : 101-5.
 
13) Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999 ; 40 : 458-61.
PubMed
14) Yamada H, Takamori K. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial 2008 ; 12 : 355-9.
PubMed
15) French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome : our current understanding. Int Immunopharmacol 2006 ; 6 : 543-9.
PubMed
16) Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis : a systematic review and meta-analysis. Br J Dermatol 2012 ; 167 : 424-32.
PubMed
P.207 掲載の参考文献
1) von Rittershain GR. Die exfoliative Dermatitis jungerer Sauglinge. Central Zeitung Kinderheilk 1878 ; 2 : 3-23.
 
2) Lyell A. Toxic epidermal necrolysis : an eruption resembling scalding of the skin. Br J Dermatol 1956 ; 68 : 355-61.
PubMed
3) Lyell A. Review of toxic epidermal necrolysis in Great Britain. Br J Dermatol 1967 ; 79 : 662-71.
PubMed
4) Melish ME, Glasgow LA. The staphylococcal scalded-skin syndrome. N Engl J Med 1970 ; 282 : 1114-9.
PubMed
5) Amagai M, Matsuyoshi N, Wang ZH, et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000 ; 6 : 1275-7.
PubMed
6) Hanakawa Y, Schechter NM, Lin C, et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002 ; 110 : 53-60.
PubMed
7) Hanakawa Y, Selwood T, Woo D, et al. Calcium-dependent conformation of desmoglein 1 is required for its cleavage by exfoliative toxin. J Invest Dermatol 2003 ; 121 : 383-9.
PubMed
8) 多田讓治. 毒素関連性疾患. 玉置邦彦, ほか編. 最新皮膚科学大系 14. 細菌・真菌性疾患. 東京 : 中山書店 ; 2003. pp99-110.
 
9) 日野治子. 伝染性膿痂疹 (SSSSを含む). 皮膚臨床 2009 ; 51 : 1592-8.
 
10) 馬場直子. 小児の膿皮症. MB Derma 2007 ; 127 : 1-8.
 
11) 荒田次郎. 浅在性細菌感染症. 玉置邦彦, ほか編. 最新皮膚科学大系 14. 細菌・真菌性疾患. 東京 : 中山書店 ; 2003. pp53-72.
 
P.215 掲載の参考文献
1) Bickers DR, Frank J. The porphyrias. In : Goldsmith LA, et al, editors. Fitzpatrick's Dermatology in Generel Medicine. 8th ed. New York : McGraw-Hill ; 2012. pp1538-73.
 
2) Watley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008 ; 83 : 408-14.
PubMed
3) 近藤雅雄, 矢野雄三, 浦田郡平. 日本の遺伝性ポルフィリン症-1920年 (第1例報告) から91年間 (2010年) の集計. ALA-Porphyrin Science 2012 ; 2 : 73-82.
 
4) 中野創. 皮膚科セミナリウム 1. 遺伝子診断と皮膚疾患. 日皮会誌 2012 ; 122 : 2057-63.
 
5) Kondo M, Yano Y, Shirataka M, et al. Porphyrias in Japan : compilation of all cases reported through 2002. Int J Hematol 2004 ; 79 : 448-56.
PubMed
6) Emiliani C, Delmelle M. Lipid solubility of porphyrins modulates their phototoxicity in membrane models. Photochem Photobiol 1983 ; 37 : 487-90.
 
7) Poh-Fitzpatrick MB, Woodley DT. Cutaneous porphyrias. In : Kanitakis J, et al, editors. Diagnostic Immunohistochemistry of the Skin. 1st ed. London : Chapman & Hall Medical ; 1998. pp202-12.
 
8) Schnait FG, Wolff K, Konrad K. Erythropoietic protoporphyria-submicroscopic events during the acute photosensitivity flare. Br J Dermatol 1975 ; 92 : 545-57.
PubMed
9) Rimington C, Magnus IA, Ryan EA, et al. Porphyria and photosensitivity. Quart J Med 1967 ; 36 : 29.
 
10) Wolff K, Honigsmann H, Rauschmeier W, et al. Microscopic and fine structural aspects of porphyrias. Acta Derm Venereol Suppl (Stockh) 1982 ; 100 : 17-28.
PubMed
11) Klein GF, Hintner H, Schuler G, et al. Junctional blisters in acquired bullous disorders of the dermal-epidermal junction zone : role of the lamina lucida as the mechanical locus minoris resistentiae. Br J Dermatol 1983 ; 109 : 499-508.
PubMed
12) 舛岡恵律子, 尾藤利憲, 岡昌宏, ほか. 遺伝子解析により診断した異型ポルフィリン症の1例. 皮膚臨床 2011 ; 53 : 277-82.
 
13) 山田英明, 中尾由絵, 中野創, ほか. 異型ポルフィリン症の1例. 臨皮 2012 ; 66 : 865-9.
 
14) 野中薫雄. ポルフィリン症. 玉置邦彦, ほか編. 最新皮膚科学大系 10. 内分泌・代謝異常症 脂肪組織疾患 形成異常症 異物沈着症. 東京 : 中山書店 ; 2003. pp81-94.
 
15) 川田暁, 上出良一, 川原繁. 遺伝性ポルフィリン症の光線過敏にたいする新規治療薬開発と有用性の検討. 厚生労働省科学研究費補助金・難治性疾患克服研究事業 遺伝性ポルフィリン症 : 新病型の診断法と新しい診療ガイドラインの確立に関する研究 平成24年度総括・分担研究報告書. 2013. pp35-7.
 
P.223 掲載の参考文献
1) Requena L, Requena C. Histopathology of the more common viral skin infections. Actas Dermosifiliogr 2010 ; 101 : 201-16.
PubMed
2) 日野治子. 2011年に大流行した手足口病の病態. 臨皮 2012 ; 66 : 16-22.
 
3) 鷲崎久美子, 小原芙美子, 高田裕子, ほか. 2011年に流行した手足口病症例のまとめ. 皮膚病診療 2012 ; 34 : 473-6.
 
4) Morizane S, Suzuki D, Tsuji K, et al. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br J Dermatol 2005 ; 153 : 981-6.
PubMed

書評

最近チェックした商品履歴

Loading...